Scarica l'app Stockscreener
2.4599
3.36%
0.0799
Annovis Bio Inc Borsa (ANVS) Ultime notizie
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - MSN
HC Wainwright Has Optimistic View of Annovis Bio Q2 Earnings - Defense World
Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Annovis Bio (NYSE:ANVS) Price Target Cut to $12.00 by Analysts at HC Wainwright - Defense World
Annovis Bio (ANVS) Price Target Cut by 60% by HC Wainwright | AN - GuruFocus
Annovis Bio stock price target cut to $12 at H.C. Wainwright By Investing.com - Investing.com South Africa
Annovis Bio stock price target cut to $12 at H.C. Wainwright - Investing.com Nigeria
Annovis Bio (ANVS) Price Target Slashed by H.C. Wainwright | ANVS Stock News - GuruFocus
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MSN
Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates - citybuzz -
Annovis to Host Webinar and Live Q&A on June 24, 2025 - GlobeNewswire
Annovis Bio, Inc. to Host Live Webcast on Neurodegenerative Disease Developments and Phase 3 Trial Updates - Nasdaq
Annovis CEO Reveals Latest Alzheimer's Phase 3 Data and FDA Feedback on Parkinson's Program - Stock Titan
Annovis Bio (ANVS) Stock Surges Over 28% | ANVS Stock News - GuruFocus
Northern Trust Corp Acquires 10,846 Shares of Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Jane Street Group LLC - Defense World
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm Before October 18, 2021 - The Globe and Mail
Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus
Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus
Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - The Manila Times
Annovis Bio Appoints New Principal Financial Officer - TipRanks
Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com
Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq
Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN
Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -
Annovis Bio hires new director of biostatistics amid AD trial - Investing.com
Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com
Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan
LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):